758689-08-6

Basic information

• Product Name: N-[4-(trifluoromethyl)phenyl]-4-(2-pyridinyl)-1,3-thiazol-2-amine
• Synonyms: N-[4-(trifluoromethyl)phenyl]-4-(2-pyridinyl)-1,3-thiazol-2-amine
• CAS NO: 758689-08-6
• Molecular Weight: 321.326
• Mol File: 758689-08-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-[4-(trifluoromethyl)phenyl]-4-(2-pyridinyl)-1,3-thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(trifluoromethyl)phenyl]-4-(2-pyridinyl)-1,3-thiazol-2-amine(758689-08-6)
• EPA Substance Registry System: N-[4-(trifluoromethyl)phenyl]-4-(2-pyridinyl)-1,3-thiazol-2-amine(758689-08-6)

Safety Data

• Hazardous Substances Data: 758689-08-6(Hazardous Substances Data)

Upstream product

• 40086-66-6 2-Bromoacetylpyridine 
• 1736-72-7 1-(4-(trifluoromethyl)phenyl)thiourea 
• 1122-62-9 2-acetylpyridine 
• 17570-98-8 2-(bromoacetyl)pyridine hydrobromide 
• 117174-71-7 N-((4-trifluoromethylphenyl)thiocarbamoyl)benzamide 
• 455-14-1 4-trifluoromethylphenylamine 

Relevant articles and documents

Antibacterial synergist, preparation method and uses thereof

The present invention relates to an antibacterial synergist, a preparation method and uses thereof, and specifically discloses a compound represented by a formula (I) and having antibacterial synergyactivity, or an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof, and a preparation method thereof. The present invention further discloses a medical composition containing the compound, and uses thereof. According to the present invention, the compound can effectively enhance the antibacterial activity of polymyxin B against Acinetobacter baumannii and Klebsiella pneumoniae, and can be used for the antibacterial treatment of pathogenic bacteria insensitive to polymyxin or having low bacterial inhibition activity. The formula (I) is defined in the specification.

Structure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl) -1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 μM or 0.008 μg/mL in 7H9 media and therapeutic index of nearly ～300. However, 55 is rapidly metabolized by human liver microsomes (t1/2 = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of ～10-5.